For more than 20 years, Bio€quity Europe has been where CEOs and investors gather to network, partner, and debate critical issues facing the biotech industry.
IQVIA are pleased to be hosting a breakfast session on day two of the conference, May 14, with a panel discussion on navigating value creation.
Navigating value creation: realising your asset’s potential along the clinical development plan.
May 14, 8:30-9:30 @Bio€quity
Session outline:
With M&A continuing to drive investment in the biopharma space, optimizing the right time to exit is essential for rising above the noise. What are the key catalysts and what kind of data will maximally influence an asset’s value and determine the scale of value inflection across the clinical development plan?
This panel of VCs and biotech CEOs will discuss the implications of alternative exit plans and strategies when seeking investment and debate the impact on the value and risk associated with asset valuation in current deal-making scenarios.
During the session we will present the insights of ourupcoming whitepaper Inflection point: How clinical trial results impact biopharma valuations.
Presenter: Joe Hopcraft, Senior Client Partner, IQVIA
Panel members:Chair: Michelle Morgan, Vice President, Biotech Lead, EMEA, IQVIA
Flexible solutions. Responsive teams. Data-driven insights.
.svg){kind=icon}
